Does the media prefer ALMR or CYRX?

In the previous week, Alamar Biosciences had 6 more articles in the media than CryoPort. MarketBeat recorded 17 mentions for Alamar Biosciences and 11 mentions for CryoPort. CryoPort's average media sentiment score of 0.78 beat Alamar Biosciences' score of 0.57 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 2 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable earnings & valuation, CYRX or FTRE?

CryoPort has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $186.45M 4.09 $78.30M -$0.90 N/A Fortrea $2.72B 0.62 -$986.20M -$0.91 N/A

Is CYRX or FTRE more profitable?

Fortrea has a net margin of -3.18% compared to CryoPort's net margin of -20.05%. Fortrea's return on equity of 10.72% beat CryoPort's return on equity. Company Net Margins Return on Equity Return on Assets CryoPort -20.05% -7.20% -4.30% Fortrea -3.18% 10.72% 2.17%

Does the media prefer CYRX or FTRE?

In the previous week, CryoPort and CryoPort both had 11 articles in the media. Fortrea's average media sentiment score of 0.96 beat CryoPort's score of 0.78 indicating that Fortrea is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Fortrea 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CYRX or MRVI?

In the previous week, CryoPort had 6 more articles in the media than Maravai LifeSciences. MarketBeat recorded 11 mentions for CryoPort and 5 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.88 beat CryoPort's score of 0.78 indicating that Maravai LifeSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Maravai LifeSciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor CYRX or BLFS?

In the previous week, CryoPort had 7 more articles in the media than BioLife Solutions. MarketBeat recorded 11 mentions for CryoPort and 4 mentions for BioLife Solutions. CryoPort's average media sentiment score of 0.78 beat BioLife Solutions' score of 0.77 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive BioLife Solutions 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, CYRX or PSNL?

CryoPort has higher revenue and earnings than Personalis. CryoPort is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $186.45M 4.09 $78.30M -$0.90 N/A Personalis $69.65M 21.42 -$81.27M -$1.09 N/A

Is CYRX or PSNL more profitable?

CryoPort has a net margin of -20.05% compared to Personalis' net margin of -153.84%. CryoPort's return on equity of -7.20% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets CryoPort -20.05% -7.20% -4.30% Personalis -153.84% -46.47% -35.30%

Does the media refer more to CYRX or PSNL?

In the previous week, CryoPort had 6 more articles in the media than Personalis. MarketBeat recorded 11 mentions for CryoPort and 5 mentions for Personalis. Personalis' average media sentiment score of 0.89 beat CryoPort's score of 0.78 indicating that Personalis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Personalis 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CryoPort (CYRX) Competitors

$15.07 -0.06 (-0.40%)

As of 01:29 PM Eastern

Compare

CYRX vs. ALMR, FTRE, MRVI, BLFS, and PSNL

Should you buy CryoPort stock or one of its competitors? CryoPort's main competitors and comparable companies include Alamar Biosciences (ALMR), Fortrea (FTRE), Maravai LifeSciences (MRVI), BioLife Solutions (BLFS), and Personalis (PSNL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does CryoPort compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and CryoPort (NASDAQ:CYRX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

CryoPort has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$74.21M	30.69	-$29.82M	-$1.74	N/A
CryoPort	$186.45M	4.09	$78.30M	-$0.90	N/A

Alamar Biosciences has a net margin of 0.00% compared to CryoPort's net margin of -20.05%. Alamar Biosciences' return on equity of 0.00% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
CryoPort	-20.05%	-7.20%	-4.30%

Alamar Biosciences currently has a consensus price target of $31.80, indicating a potential downside of 3.11%. CryoPort has a consensus price target of $18.00, indicating a potential upside of 19.45%. Given CryoPort's stronger consensus rating and higher probable upside, analysts plainly believe CryoPort is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Alamar Biosciences had 6 more articles in the media than CryoPort. MarketBeat recorded 17 mentions for Alamar Biosciences and 11 mentions for CryoPort. CryoPort's average media sentiment score of 0.78 beat Alamar Biosciences' score of 0.57 indicating that CryoPort is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	2 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

92.9% of CryoPort shares are held by institutional investors. 9.5% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

CryoPort beats Alamar Biosciences on 10 of the 15 factors compared between the two stocks.

How does CryoPort compare to Fortrea?

CryoPort (NASDAQ:CYRX) and Fortrea (NASDAQ:FTRE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

In the previous week, CryoPort and CryoPort both had 11 articles in the media. Fortrea's average media sentiment score of 0.96 beat CryoPort's score of 0.78 indicating that Fortrea is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Fortrea	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CryoPort has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market. Comparatively, Fortrea has a beta of 1.99, meaning that its share price is 99% more volatile than the broader market.

CryoPort presently has a consensus price target of $18.00, indicating a potential upside of 19.45%. Fortrea has a consensus price target of $20.75, indicating a potential upside of 17.18%. Given CryoPort's stronger consensus rating and higher possible upside, equities analysts plainly believe CryoPort is more favorable than Fortrea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

CryoPort has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$186.45M	4.09	$78.30M	-$0.90	N/A
Fortrea	$2.72B	0.62	-$986.20M	-$0.91	N/A

92.9% of CryoPort shares are owned by institutional investors. 9.5% of CryoPort shares are owned by insiders. Comparatively, 0.7% of Fortrea shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Fortrea has a net margin of -3.18% compared to CryoPort's net margin of -20.05%. Fortrea's return on equity of 10.72% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-20.05%	-7.20%	-4.30%
Fortrea	-3.18%	10.72%	2.17%

Summary

CryoPort beats Fortrea on 9 of the 15 factors compared between the two stocks.

How does CryoPort compare to Maravai LifeSciences?

CryoPort (NASDAQ:CYRX) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

CryoPort has a net margin of -20.05% compared to Maravai LifeSciences' net margin of -37.07%. CryoPort's return on equity of -7.20% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-20.05%	-7.20%	-4.30%
Maravai LifeSciences	-37.07%	-15.34%	-7.72%

CryoPort has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

In the previous week, CryoPort had 6 more articles in the media than Maravai LifeSciences. MarketBeat recorded 11 mentions for CryoPort and 5 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.88 beat CryoPort's score of 0.78 indicating that Maravai LifeSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Maravai LifeSciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 9.5% of CryoPort shares are owned by insiders. Comparatively, 2.5% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CryoPort presently has a consensus price target of $18.00, indicating a potential upside of 19.45%. Maravai LifeSciences has a consensus price target of $6.25, indicating a potential upside of 10.13%. Given CryoPort's stronger consensus rating and higher possible upside, equities analysts plainly believe CryoPort is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

CryoPort has higher revenue and earnings than Maravai LifeSciences. CryoPort is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$186.45M	4.09	$78.30M	-$0.90	N/A
Maravai LifeSciences	$185.74M	7.89	-$130.77M	-$0.52	N/A

Summary

CryoPort beats Maravai LifeSciences on 12 of the 16 factors compared between the two stocks.

How does CryoPort compare to BioLife Solutions?

CryoPort (NASDAQ:CYRX) and BioLife Solutions (NASDAQ:BLFS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

BioLife Solutions has a net margin of 53.29% compared to CryoPort's net margin of -20.05%. BioLife Solutions' return on equity of 2.70% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-20.05%	-7.20%	-4.30%
BioLife Solutions	53.29%	2.70%	2.49%

92.9% of CryoPort shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 9.5% of CryoPort shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, CryoPort had 7 more articles in the media than BioLife Solutions. MarketBeat recorded 11 mentions for CryoPort and 4 mentions for BioLife Solutions. CryoPort's average media sentiment score of 0.78 beat BioLife Solutions' score of 0.77 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
BioLife Solutions	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CryoPort has higher revenue and earnings than BioLife Solutions. CryoPort is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$186.45M	4.09	$78.30M	-$0.90	N/A
BioLife Solutions	$96.21M	17.79	-$4.59M	$1.16	30.20

CryoPort presently has a consensus target price of $18.00, suggesting a potential upside of 19.45%. BioLife Solutions has a consensus target price of $31.38, suggesting a potential downside of 10.45%. Given CryoPort's stronger consensus rating and higher probable upside, equities research analysts clearly believe CryoPort is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18

CryoPort has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market.

Summary

BioLife Solutions beats CryoPort on 9 of the 17 factors compared between the two stocks.

How does CryoPort compare to Personalis?

CryoPort (NASDAQ:CYRX) and Personalis (NASDAQ:PSNL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 61.9% of Personalis shares are owned by institutional investors. 9.5% of CryoPort shares are owned by insiders. Comparatively, 4.2% of Personalis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

CryoPort has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market. Comparatively, Personalis has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market.

CryoPort presently has a consensus target price of $18.00, suggesting a potential upside of 19.45%. Personalis has a consensus target price of $14.25, suggesting a potential upside of 0.01%. Given CryoPort's stronger consensus rating and higher probable upside, analysts clearly believe CryoPort is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Personalis	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

CryoPort has a net margin of -20.05% compared to Personalis' net margin of -153.84%. CryoPort's return on equity of -7.20% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-20.05%	-7.20%	-4.30%
Personalis	-153.84%	-46.47%	-35.30%

In the previous week, CryoPort had 6 more articles in the media than Personalis. MarketBeat recorded 11 mentions for CryoPort and 5 mentions for Personalis. Personalis' average media sentiment score of 0.89 beat CryoPort's score of 0.78 indicating that Personalis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Personalis	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CryoPort has higher revenue and earnings than Personalis. CryoPort is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$186.45M	4.09	$78.30M	-$0.90	N/A
Personalis	$69.65M	21.42	-$81.27M	-$1.09	N/A

Summary

CryoPort beats Personalis on 12 of the 16 factors compared between the two stocks.

Get CryoPort News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYRX vs. The Competition

Export

Metric	CryoPort	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$763.03M	$9.47B	$6.98B	$13.02B
Dividend Yield	N/A	1.46%	2.58%	10.72%
P/E Ratio	-16.74	60.40	269.27	25.25
Price / Sales	4.09	105.59	597.31	101.05
Price / Cash	N/A	26.03	70.53	50.75
Price / Book	1.72	37.99	13.07	6.33
Net Income	$78.30M	$56.66B	$3.45B	$347.81M
7 Day Performance	-0.34%	0.21%	0.74%	0.90%
1 Month Performance	-6.23%	1.47%	1.40%	0.89%
1 Year Performance	70.27%	19.33%	67.03%	20.36%

CryoPort Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYRX CryoPort	3.3137 of 5 stars	$15.07 -0.4%	$18.00 +19.5%	+66.6%	$763.03M	$186.45M	N/A	1,186	Insider Trade
ALMR Alamar Biosciences	1.0747 of 5 stars	$28.35 +4.6%	$30.00 +5.8%	N/A	$1.96B	$87.16M	N/A	222	News Coverage Earnings Report Analyst Forecast
FTRE Fortrea	3.9193 of 5 stars	$19.05 +5.9%	$20.75 +8.9%	+127.3%	$1.71B	$2.68B	N/A	14,300
MRVI Maravai LifeSciences	3.0718 of 5 stars	$6.41 -0.3%	$5.50 -14.2%	+110.2%	$1.66B	$185.74M	N/A	610
BLFS BioLife Solutions	3.0806 of 5 stars	$33.80 +3.9%	$31.38 -7.2%	+37.2%	$1.59B	$96.21M	N/A	440	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYRX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CryoPort (CYRX) Competitors

CYRX vs. ALMR, FTRE, MRVI, BLFS, and PSNL

How does CryoPort compare to Alamar Biosciences?

Summary

How does CryoPort compare to Fortrea?

Summary

How does CryoPort compare to Maravai LifeSciences?

Summary

How does CryoPort compare to BioLife Solutions?

Summary

How does CryoPort compare to Personalis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX vs. The Competition

CryoPort Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CryoPort (CYRX) Competitors

CYRX vs. ALMR, FTRE, MRVI, BLFS, and PSNL

How does CryoPort compare to Alamar Biosciences?

Which has higher earnings and valuation, ALMR or CYRX?

Is ALMR or CYRX more profitable?

Do analysts rate ALMR or CYRX?

Does the media prefer ALMR or CYRX?

Do insiders & institutionals believe in ALMR or CYRX?

Summary

How does CryoPort compare to Fortrea?

Does the media prefer CYRX or FTRE?

Which has more risk & volatility, CYRX or FTRE?

Do analysts recommend CYRX or FTRE?

Which has preferable earnings & valuation, CYRX or FTRE?

Do insiders & institutionals believe in CYRX or FTRE?

Is CYRX or FTRE more profitable?

Summary

How does CryoPort compare to Maravai LifeSciences?

Is CYRX or MRVI more profitable?

Which has more risk & volatility, CYRX or MRVI?

Does the media prefer CYRX or MRVI?

Do insiders and institutionals have more ownership in CYRX or MRVI?

Do analysts prefer CYRX or MRVI?

Which has stronger valuation & earnings, CYRX or MRVI?

Summary

How does CryoPort compare to BioLife Solutions?

Is CYRX or BLFS more profitable?

Do insiders and institutionals have more ownership in CYRX or BLFS?

Does the media favor CYRX or BLFS?

Which has higher valuation & earnings, CYRX or BLFS?

Do analysts prefer CYRX or BLFS?

Which has more volatility & risk, CYRX or BLFS?

Summary

How does CryoPort compare to Personalis?

Do institutionals & insiders have more ownership in CYRX or PSNL?

Which has more volatility & risk, CYRX or PSNL?

Do analysts prefer CYRX or PSNL?

Is CYRX or PSNL more profitable?

Does the media refer more to CYRX or PSNL?

Which has higher valuation & earnings, CYRX or PSNL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX vs. The Competition

CryoPort Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools